Discovery of potent, selective chymase inhibitors via fragment linking strategies.
暂无分享,去创建一个
Daniel R. Albaugh | Ming-Hong Hao | M. Hao | J. Proudfoot | Asitha Abeywardane | Leslie Martin | Steven J Taylor | S. De Lombaert | A. Padyana | Daniel R Albaugh | Hidenori Takahashi | Hidenori Takahashi | Shuang Liang | Melissa Hill-Drzewi | Bennett Farmer | S. Pullen | Stéphane De Lombaert | Asitha Abeywardane | Shuang Liang | Anil K Padyana | Melissa Hill-Drzewi | Brandon Collins | John Proudfoot | Leslie Martin | Bennett S Farmer | Xiang Li | Steven S Pullen | Xiang Li | Brandon K Collins
[1] I. Bot,et al. Mast cells in atherosclerosis , 2011, Thrombosis and Haemostasis.
[2] C. Pemberton,et al. Cardiac chymase converts rat proAngiotensin-12 (PA12) to angiotensin II: effects of PA12 upon cardiac haemodynamics. , 2009, Cardiovascular research.
[3] K. Amin. The role of mast cells in allergic inflammation. , 2012, Respiratory medicine.
[4] P. Veeraveedu,et al. Chymase Inhibition Reduces the Progression to Heart Failure After Autoimmune Myocarditis in Rats , 2007, Experimental biology and medicine.
[5] Christopher W Murray,et al. Fragment-based lead discovery: leads by design. , 2005, Drug discovery today.
[6] L. Groome,et al. Chymotrypsin-Like Protease (Chymase) Mediates Endothelial Activation by Factors Derived From Preeclamptic Placentas , 2009, Reproductive Sciences.
[7] A. Hopkins,et al. Emerging role of surface plasmon resonance in fragment-based drug discovery. , 2011, Future medicinal chemistry.
[8] S. Takai,et al. Chymase Plays an Important Role in Left Ventricular Remodeling Induced by Intermittent Hypoxia in Mice , 2009, Hypertension.
[9] G. Caughey. Mast cell proteases as protective and inflammatory mediators. , 2011, Advances in experimental medicine and biology.
[10] G. Siegal,et al. Target Immobilization as a Strategy for NMR-Based Fragment Screening , 2010, Journal of biomolecular screening.
[11] M. Tuck,et al. Studies examining risk reduction in subjects with multiple metabolic and cardiovascular risk factors , 2000, Current hypertension reports.
[12] P. Emsley,et al. Features and development of Coot , 2010, Acta crystallographica. Section D, Biological crystallography.
[13] Robert Abel,et al. Motifs for molecular recognition exploiting hydrophobic enclosure in protein–ligand binding , 2007, Proceedings of the National Academy of Sciences.
[14] J. S. Janicki,et al. Cardiac mast cell regulation of matrix metalloproteinase-related ventricular remodeling in chronic pressure or volume overload. , 2006, Cardiovascular research.
[15] S. Takai,et al. Targets of chymase inhibitors , 2011, Expert opinion on therapeutic targets.
[16] E. Oliveira,et al. Alternative pathways for angiotensin II generation in the cardiovascular system. , 2011, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.
[17] S. Takai,et al. Chymase Inhibition Prevents Cardiac Fibrosis and Dysfunction after Myocardial Infarction in Rats , 2006, Hypertension Research.
[18] Paul D. Leeson,et al. The influence of the 'organizational factor' on compound quality in drug discovery , 2011, Nature Reviews Drug Discovery.
[19] N. Meanwell. Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety. , 2011, Chemical research in toxicology.
[20] S. Takai,et al. Purification and characterization of angiotensin II-generating chymase from hamster cheek pouch. , 1996, Life sciences.
[21] S. Takai,et al. Chronic chymase inhibition preserves cardiac function after left ventricular repair in rats. , 2008, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.
[22] S. Doggrell,et al. Cardiac chymase: pathophysiological role and therapeutic potential of chymase inhibitors. , 2005, Canadian journal of physiology and pharmacology.
[23] S. Takai,et al. Multiple mechanisms for the action of chymase inhibitors. , 2012, Journal of pharmacological sciences.
[24] M. Arooj,et al. 3D QSAR Pharmacophore Modeling, in Silico Screening, and Density Functional Theory (DFT) Approaches for Identification of Human Chymase Inhibitors , 2011, International journal of molecular sciences.
[25] S. Takai,et al. Chymase-dependent angiotensin II formation in human vascular tissue. , 1999, Circulation.
[26] Randy J. Read,et al. Acta Crystallographica Section D Biological , 2003 .
[27] Gerald T Miwa,et al. Bioactivation of drugs: risk and drug design. , 2011, Annual review of pharmacology and toxicology.
[28] Nirmal Singh,et al. Mast cells: an expanding pathophysiological role from allergy to other disorders , 2012, Naunyn-Schmiedeberg's Archives of Pharmacology.
[29] S. Savvides,et al. Discovery of potent, selective, orally active, nonpeptide inhibitors of human mast cell chymase. , 2007, Journal of medicinal chemistry.
[30] J. Sadoshima,et al. Knocking Out Angiotensin II in the Heart , 2011, Current hypertension reports.
[31] Daniel R. Albaugh,et al. Benzimidazolone as potent chymase inhibitor: modulation of reactive metabolite formation in the hydrophobic (P1) region. , 2011, Bioorganic & medicinal chemistry letters.
[32] P. Cummins. A new addition to the renin-angiotensin peptide family: proAngiotensin-12 (PA12). , 2009, Cardiovascular research.
[33] T. Denney,et al. Chymase Inhibition Prevents Fibronectin and Myofibrillar Loss and Improves Cardiomyocyte Function and LV Torsion Angle in Dogs With Isolated Mitral Regurgitation , 2010, Circulation.
[34] K. Okoń,et al. Mast cells and cancer: enemies or allies? , 2012, Polish journal of pathology : official journal of the Polish Society of Pathologists.
[35] Narayanasami Sukumar,et al. A Novel, Potent Dual Inhibitor of the Leukocyte Proteases Cathepsin G and Chymase , 2005, Journal of Biological Chemistry.
[36] S. Takai,et al. New approaches to blockade of the renin-angiotensin-aldosterone system: chymase as an important target to prevent organ damage. , 2010, Journal of pharmacological sciences.
[37] F. Sellke,et al. Chymase Inhibition Reduces Infarction and Matrix Metalloproteinase-9 Activation and Attenuates Inflammation and Fibrosis after Acute Myocardial Ischemia/Reperfusion , 2011, Journal of Pharmacology and Experimental Therapeutics.
[38] Allen B Reitz,et al. Hit triage using efficiency indices after screening of compound libraries in drug discovery. , 2009, Current topics in medicinal chemistry.